Genetic Signatures CEO presentation at the 7th Annual Australian Microcap Investment Conference

• Genetic Signatures to present its global growth strategy for the development and supply of world leading molecular diagnostic products 
• The largest conference in Australia focused on microcap investment opportunities 
• Presentations from the CEOs of 24 of Australia’s leading emerging companies 

Molecular Diagnostic (MDx) company Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that Chief Executive Officer, John Melki, PhD., will deliver today at the 7th Annual Australian Microcap Investment Conference.

Dr Melki will present on Genetic Signatures’ commercialisation progress, financial results, and achievements to date. The presentation will also detail the Company’s global growth strategy for the sale of world leading solutions for the rapidly growing infectious disease detection market.

Dr Melki said: “2016 was a successful year for Genetic Signatures with record sales revenues and completion of a $15M capital raising. I am looking forward to updating the microcap conference attendees on our progress over the last 12 months and how we are driving shareholder value by accelerating the Company’s growth on a number of fronts.”

Click here to Download the Full Press Release & Presentation